Biomarker Synergy in Relapsing Multiple Sclerosis: Neurofilament Light Chain and B Cells in Relation to Disease Outcomes

Background and Objectives Anti-CD20 B-cell–depleting therapies demonstrate robust efficacy in people with multiple sclerosis (pwMS). This study addressed the limited understanding of relationships between B-cell populations before and after treatment with ocrelizumab and outcomes in people with relapsing MS (pwRMS) or primary progressive MS (pwPPMS). Methods Total circulating blood B cells and B-cell subsets were examined at baseline and longitudinally in pwRMS and pwPPMS enrolled in the pivotal Phase 3 trials (OPERA I, OPERA II, and ORATORIO). Relationships to disease outcomes before and after treatment with ocrelizumab or comparators were evaluated using generalized linear models and time-to-event analyses. Results Ocrelizumab rapidly depleted total B cells in pwRMS. Blood samples (n = 15,025) were assessed from 3 Phase 3 trials from 2,370 pwMS, demonstrating depletion in all B-cell subsets. Greater depletion was observed with higher ocrelizumab exposure and longer treatment duration. In limited pwMS with detectable B cells, the majority were mature-naive B cells. Findings from the double-blind treatment period considered robust were that pwRMS with detectable mature-naive, memory, or total B cells had greater risk of developing new/enlarging T2 lesions (odds ratio: 3.8–4.9; p < 0.001), while pwPPMS with higher circulating plasmablasts had greater thalamic volume loss (β: −1.4; p < 0.001). Above-median baseline memory B-cell levels identified interferon beta-1a–treated pwRMS at greater risk of disability progression (hazard ratio: 2.0; p < 0.01), with larger numbers of slowly expanding lesions ( p < 0.01). When interferon beta-1a–treated pwRMS presented both high baseline B cells and high serum neurofilament light (NfL; B cells/NfL high), they showed an even higher risk of disability progression (HR: 3.10; p < 0.001). Treatment with ocrelizumab in this subgroup of pwRMS with B cells/NfL high resulted in a near 4-fold reduction in risk of disability progression (HR: 0.25, p < 0.001). Discussion Ocrelizumab treatment depleted total B cells and all B-cell subsets in an exposure-dependent and duration-dependent manner. PwRMS with detectable on-treatment B cells had greater risk of new/enlarging T2 lesions, suggesting that sustained deep B-cell depletion may be important for preventing disability worsening. High baseline B cells when present with high NfL identified a population at increased risk of disease worsening who could benefit from ocrelizumab treatment.

Authors

Institutions

Publication Details

Journal
Neurology Neuroimmunology & Neuroinflammation
Published
2026-11-12
DOI
https://doi.org/10.1212/nxi.0000000000200665
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biomarker Synergy in Relapsing Multiple Sclerosis: Neurofilament Light Chain and B Cells in Relation to Disease Outcomes

Heidemarie Kletzl, Ann E. Herman, Xiaoming Jia, Ludwig Kappos et al.
Neurology Neuroimmunology & Neuroinflammation
Multiple Sclerosis Research Studies
article

Biomarker Synergy in Relapsing Multiple Sclerosis: Neurofilament Light Chain and B Cells in Relation to Disease Outcomes

Heidemarie Kletzl, Ann E. Herman, Xiaoming Jia, Ludwig Kappos, Koji Shinoda, Harold Koendgen, Christopher T. Harp, Amit Bar‐Or, Anastasiia Raievska, Ulrike Bonati, Stephen L. Hauser, Nicolas Strauli
article en

Abstract

Background and Objectives Anti-CD20 B-cell–depleting therapies demonstrate robust efficacy in people with multiple sclerosis (pwMS). This study addressed the limited understanding of relationships between B-cell populations before and after treatment with ocrelizumab and outcomes in people with relapsing MS (pwRMS) or primary progressive MS (pwPPMS). Methods Total circulating blood B cells and B-cell subsets were examined at baseline and longitudinally in pwRMS and pwPPMS enrolled in the pivotal Phase 3 trials (OPERA I, OPERA II, and ORATORIO). Relationships to disease outcomes before and after treatment with ocrelizumab or comparators were evaluated using generalized linear models and time-to-event analyses. Results Ocrelizumab rapidly depleted total B cells in pwRMS. Blood samples (n = 15,025) were assessed from 3 Phase 3 trials from 2,370 pwMS, demonstrating depletion in all B-cell subsets. Greater depletion was observed with higher ocrelizumab exposure and longer treatment duration. In limited pwMS with detectable B cells, the majority were mature-naive B cells. Findings from the double-blind treatment period considered robust were that pwRMS with detectable mature-naive, memory, or total B cells had greater risk of developing new/enlarging T2 lesions (odds ratio: 3.8–4.9; p < 0.001), while pwPPMS with higher circulating plasmablasts had greater thalamic volume loss (β: −1.4; p < 0.001). Above-median baseline memory B-cell levels identified interferon beta-1a–treated pwRMS at greater risk of disability progression (hazard ratio: 2.0; p < 0.01), with larger numbers of slowly expanding lesions ( p < 0.01). When interferon beta-1a–treated pwRMS presented both high baseline B cells and high serum neurofilament light (NfL; B cells/NfL high), they showed an even higher risk of disability progression (HR: 3.10; p < 0.001). Treatment with ocrelizumab in this subgroup of pwRMS with B cells/NfL high resulted in a near 4-fold reduction in risk of disability progression (HR: 0.25, p < 0.001). Discussion Ocrelizumab treatment depleted total B cells and all B-cell subsets in an exposure-dependent and duration-dependent manner. PwRMS with detectable on-treatment B cells had greater risk of new/enlarging T2 lesions, suggesting that sustained deep B-cell depletion may be important for preventing disability worsening. High baseline B cells when present with high NfL identified a population at increased risk of disease worsening who could benefit from ocrelizumab treatment.

Neurology Neuroimmunology & NeuroinflammationVol. 14(1)
F. Hoffmann-La Roche AG (CH), University of California, San Francisco (US), Genentech (US), University Hospital of Basel (CH), University of Pennsylvania (US)
Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Sanofi, Biogen, Celgene, University of Pennsylvania, F. Hoffmann-La Roche, Atara Biotherapeutics, Kiniksa Pharmaceuticals, Celltrion, NGM Biopharmaceuticals, Moderna, Horizon Therapeutics, Galápagos, Shionogi, Idorsia Pharmaceuticals, Genentech, EMD Serono, Novartis Pharma
Good health and well-being
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon